Friday, 17 Jan 2020

You are here

Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis

Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.

A multicenter, retrospective study assessed the effect of rituximab on autoantibodies and immunoglobulin levels, and clinical outcomes in 239 AAV patients.

During RTX induction phase (n=53 patients), there was a decline in IgG levels (6% per month) and ANCA levels (47%) - this included a similar fall in anti-MPO and anti-PR3 titers.

During RTX maintenance treatment (over a median 2.4 yrs), a decline in IgG levels (0.6% per year) was seen. Significant hypogammaglobulinemia (IgG < 400 mg/dL) occurred in 4.6% of patients. Serious infections during maintenance occurred at a rate of 8.5 [95% CI, 0.66 to 1.1] per 100 patient years and were independently associated with an IgG level < 400mg/dL. (Analyses of the RA cohort has shown that hypo-IgG is a risk factor for serious infection).

B cell targeted therapy with RTX does results in a decline in ANCA titers as well as total IgG levels in a minority of patients (4.6%) who may be at risk for serious infections. 

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Best of 2019 - New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.